GLP-1 Collective

Policy Tracker · Patient Lens · July 5, 2026

A dozen patients, two drugmakers, one legal argument about pricing

Courts across several states are being asked to decide whether Novo Nordisk and Eli Lilly misled patients about what drives Ozempic and Mounjaro costs.

Nothing new was filed in the last day. These are the 8 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Patient sues Novo Nordisk over GLP-1 business practices](/lawsuits/cl-73571946)**.

**[Novo Nordisk faces lawsuit over Ozempic pricing and marketing](/lawsuits/cl-73571864)**.

**[Novo Nordisk faces mystery lawsuit over GLP-1 practices](/lawsuits/cl-73569270)**.

**[Lawsuit filed against Eli Lilly over GLP-1 drugs](/lawsuits/cl-73569012)**.

**[Wright v. Novo Nordisk: What this lawsuit means for Ozempic and Wegovy](/lawsuits/cl-73568926)**.

**[Patient sues Eli Lilly over misleading GLP-1 drug claims](/lawsuits/cl-73566589)**.

**[Lawsuit targets Eli Lilly's GLP-1 marketing practices](/lawsuits/cl-73566345)**.

**[Stribling sues Novo Nordisk over Ozempic pricing and marketing](/lawsuits/cl-73564923)**.

14 further items in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.